Form 4: Processa Pharmaceuticals Executive Increases Stake

David Young, President of R&D at Processa Pharmaceuticals, acquired 1,706 shares of common stock at $2.69 per share.

Summary

• David Young, President of Research & Development at Processa Pharmaceuticals, Inc. (PCSA), purchased 1,706 shares of common stock.
• The transaction occurred on April 30, 2026, at a price of $2.69 per share.
• Following this transaction, the reporting person directly owns 13,813 shares of common stock.
• The reporting person also maintains indirect ownership of shares through the Young-Plaisance Revocable Trust (1,242 shares), family entities (432 shares), and CorLyst, LLC (742 shares).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive signal, as insider buying typically reflects management's confidence in the company's future prospects.

Positives

• Insider confidence is demonstrated by the executive's decision to increase his personal equity stake in the company.
• The purchase was made at market price, signaling alignment between management and shareholder interests.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider buying in small-cap biotechnology firms is often viewed as a positive signal regarding management's belief in the company's clinical pipeline and long-term valuation.

Comparison to Industry Standards

• Insider purchases are standard practice for executives in the pharmaceutical sector to signal confidence during development phases.
• The volume of shares purchased is relatively small, consistent with routine portfolio adjustments rather than a major strategic shift.

Stakeholder Impact

• Shareholders may interpret this purchase as a sign of internal stability and confidence from the President of R&D.

Next Steps

• NA

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Insider Trading, Form 4, Biotech, Equity Ownership